Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that the company recently entered into an agreement with Theramex HQ UK Li...
According to the news from Zhitong Finance APP, Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that the company recently signed a "Rights License and Distribution Agreement" (referred to as "this agreement" or "the agreement") with Theramex HQ UK Limited (referred to as "Theramex"). The two parties reached a cooperation agreement for the rights license and distribution of estradiol progesterone soft capsules (referred to as "Bijuva", which is its product name) for continuous combination hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women within China. Shandong Jincheng Pharmaceutical Group obtained exclusive commercial rights for this product in mainland China, Hong Kong, and Macau.
